Publication Date: 16 Mar 2014
Type: Original Research
Journal: Clinical Medicine Insights: Oncology
Citation: Clinical Medicine Insights: Oncology 2014:8 29-36
Introduction: This study aims to make an indirect comparison between enzalutamide and abiraterone acetate for mCRPC post-docetaxel.
Methods: A search for published phase 3 trials was performed with PubMed. Indirect comparisons of enzalutamide (AFFIRM) to abiraterone acetate (COU-AA-301) on outcomes overall survival (OS), time to prostate-specific-antigen (PSA) progression, radiographic progression-free survival (PFS), and PSA response were constructed in the context of log-linear regression models.
Results: There was no statistically significant difference in OS (hazard ratio (HR) 0.85, 95% CI 0.68–1.07). However, there was some evidence that enzalutamide may outperform abiraterone acetate with respect to secondary outcomes: time to PSA progression (HR 0.40, 95% CI 0.30–0.53), radiographic PFS (HR 0.61, 95% CI 0.50–0.74), and PSA response rates (RRs) (OR 10.69, 95% CI 3.92–29.20).
Conclusion: While there was no statistically significant difference in OS, enzalutamide may be advantageous for secondary endpoints. Findings of this indirect comparison serve to be hypothesis-generating for future head-to-head trials.
PDF (790.29 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I have been very pleased with the attention and dedication provided to my paper. It was very well organized and informative and all the information that I needed during the process of publication was readily available. The review process was quick and I am very satisfied with the service provided by Libertas. Thank you for your service.
Facebook Google+ Twitter
Pinterest Tumblr YouTube